08:30 AM EDT, 06/17/2025 (MT Newswires) -- Spyre Therapeutics ( SYRE ) said Tuesday that interim phase 1 results for SPY002 and SPY072, its two investigational anti-TL1A monoclonal antibodies, met all study objectives, supporting their potential as next-generation monotherapies for immune-mediated diseases.

The company said both therapies were well-tolerated in single doses up to 1500 mg, with no serious adverse events reported, and demonstrated prolonged half-lives that suppressed free TL1A for up to 20 weeks at the lowest tested dose.

Based on the data, Spyre said it is advancing SPY002 into a trial for ulcerative colitis, which began in May. The trial will also evaluate SPY001, SPY002, SPY003, and pairwise combinations under a single master protocol, it said.

The biotechnology company said SPY072 will be developed in a phase 2 study for patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, which is expected to begin in Q3.

Spyre expects to report additional updates in 2026, including open-label monotherapy data for its three anti-TL1A antibodies in ulcerative colitis and placebo-controlled data for SPY072 in the three rheumatologic conditions, the drugmaker said.

Shares of the company were 5.8% lower in recent premarket activity.